Ivermectin In Treatment of COVID 19 Patients

Not Applicable

• Conditions: Covid19
• Interventions: Drug: Ivermectin

• Registration Number: NCT04425707
• Lead Sponsor: Ministry of Health and Population, Egypt

Brief Summary

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

Detailed Description

the study will compare the effect of ivermectin in comaprison and addition to the standard mode of care for the COVID 19 patients

Study Timeline

• Status Verified: 2020-06
• Study First Submitted: 2020-06-08
• Study First Submitted QC: 2020-06-08
• Last Update Submitted: 2020-06-08
• Study Start: 2020-06-09
• Study First Posted: 2020-06-11
• Last Update Posted: 2020-06-11
• Primary Completion: 2020-07-01
• Study Completion: 2020-09-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral RNA swap

Read More

Exclusion Criteria

• Contraindications for the drug: hypersensitivity.
• Any medications with possible drug interactions.
• Severe cases.
• Any malignant condition.
• Pregnant females.
• Breast feeding females.
• Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
B standard care alone	Ivermectin	standard care will be administarted alone
C ivermectin added to standard of care	Ivermectin	ivermectin will be administarted in adition to standard care
A ivermectin alone	Ivermectin	ivermectin will be administarted alone to COVID 19 patients

Primary Outcome Measures

Name	Time	Method
to evaluate the role of Ivermectin as a line of treatment for COVID 19	2 months	the role of ivermectin in the cure of COVID 19 patients

Secondary Outcome Measures

Name	Time	Method
To asses the rate of viral clearance in comparison to other treatment protocols.	2 months	to compare the results of ivermectin with the standard care

Trial Locations

Locations (1)

isolation and referal hospitals for COVID 19 patients; 🇪🇬 Cairo, Egypt